Australian company, Vaxine Pty Ltd, has developed a protein based COVID-19 vaccine that completely blocks virus transmission to non-immune individuals. The COVAX-19™ vaccine being developed by Australian company, Vaxine Pty Ltd, is set to be a game-changer in the fight against the COVID-19 pandemic and could allow earlier re-opening of national borders after it was shown to not only protect but also to completely block virus transmission to non-immune animals.
Vaxine’s biggest challenge now is to quickly raise the financial resources to complete Phase 3 human clinical trials and get Covid-19 vaccine manufactured at large scale which is likely to be in the order of $50 million dollars.
In another major breakthrough, Vaxine have also successfully created a breakthrough multivalent vaccine to protect against the new Covid-19 virus variants including the worrying South African, Brazilian and Indian mutant strains. The results of this multivalent Covid-19 vaccine formulation in animal testing is looking very promising.
Vaxine’s COVAX-19™ vaccine is a subunit vaccine based on synthetic protein produced using harmless insect cells to which Vaxine’s proprietary Advax polysaccharide adjuvant is added as a vaccine turbocharger to maximise the vaccine’s effectiveness and durability.
Vaxine is currently working with partners in overseas countries to assist in the upcoming phase 3 human clinical trials.
Vaxine has a long history of successfully developing pandemic vaccines, having previously developed vaccines against the SARS 3 and MERS coronaviruses that were shown to be highly protective in relevant animal models.
The European Chemicals Agency (ECHA) has amended the Prior Informed Consent (PIC) Regulation, EU 64/2012, to add 27 pesticides and eight industrial chemicals into Annex I, bringing the total to 295. As a result, EU exporters are now required to notify their intentions to export them from 1 November onwards.
The global custom synthesis and manufacturing market was valued at US$271.33 billion in 2022. The market value is expected to reach US$474.94 billion by 2028.
The ocean freight industry is undergoing a massive transformation, as the technology and supply chain management tools are being improved by the day, impacting ocean freight rates.
In the second half of 2022, China unveiled the details of its data export regulations, providing further explanations to its existing laws and regulations on data.
The current energy crisis has reached an unsustainable level for the European chemical industry. For the first time ever, the EU imports more chemicals than it exports, both in volume and value, resulting in a trade deficit of € 5.6 bn for the first half of 2022.
Endocrine Disrupting Chemicals (also referred to as hormone disruptors or EDCs) are synthetic chemicals that are not produced by the human body and that disrupt the normal functioning of humans and animals.
The shipping industry is now returning to normality and is in a downward spiral. The cost of shipping goods from China has slumped to the lowest level in more than two years as the world economy stumbles, dimming prospects for container carriers that turned in record profits during the pandemic.
No precipitous plunge in container shipping rates, just ‘orderly’ decline.
The global food and beverage market size is expected to grow from $5.8 trillion in 2021 to $6.4 trillion in 2022 at a growth rate of 9.7%. The food and beverage market size is expected to grow to $8.9 trillion in 2026 at a compound annual growth rate of 8.7%.